Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease-Reference-Cited by-同舟云学术

Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease

Published:2021-11-01 Issue: Volume: Page:
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Isshiki Kyohei,Kamiya Takahiro,Endo Akifumi,Okamoto Kentaro,Osumi Tomoo,Kawai Toshinao,Arai Katsuhiro,Tomizawa Daisuke^ORCID,Ohtsuka Kazuo,Nagahori Masakazu,Imai Kohsuke,Kato Motohiro^ORCID,Kanegane Hirokazu

Funder

National Center for Child Health and Development

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-021-03245-0.pdf

Reference10 articles.

1. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.

2. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.

3. Fløisand Y, Lazarevic VL, Maertens J, Mattsson J, Shah NN, Zachée P, et al. Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review. Biol Blood Marrow Transplant. 2019;25:720–7.

4. Danylesko I, Bukauskas A, Paulson M, Peceliunas V, Gedde-Dahl DYT, Shimoni A, et al. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. Bone Marrow Transplant. 2019;54:987–93.

5. Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, Carpi JM, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care—an evidence-based guideline from European Crohn’s and colitis organization and European society of paediatric gastroenterology, hepatology and nutrition. J Pediat Gastroenterol Nutr. 2018;67:257–91.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease;Frontiers in Immunology;2024-07-03

2. Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease;Therapeutic Advances in Hematology;2024-01

3. Treatment of steroid-refractory graft versus host disease in children;Frontiers in Transplantation;2023-09-15

4. Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review;International Journal of Hematology;2023-04-19

5. Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis;Frontiers in Immunology;2022-11-11